Enjoy complimentary customisation on priority with our Enterprise License!
Cystic fibrosis is a genetic defect, which builds up thick mucus in the lungs. The thick mucus blocks the airways and damages the lungs, leading to bacterial infection. These bacteria when multiplied may often lead to a serious chronic problem. However, regular treatment can reduce these complications and ease symptoms. Also, in some instances, it has also been observed that the people with bronchiectasis tend to develop cystic fibrosis in the long term, leading to failure in the respiratory system. It generally occurs due to a defect in both the copies of the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. People with cystic fibrosis have high salt levels, and the severity of cystic fibrosis differs from person to person. Globally, over 70,000 people are living with cystic fibrosis with about 30,000 of them hailing from the US. Consequently, Technavio’s market research analysts suggest that rising number of incidences of cystic fibrosis is one of the key factors promoting the drug development for cystic fibrosis.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for treatment of cystic fibrosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of gene therapy molecules for the treatment of cystic fibrosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
The oral route of administration (ROA) involves the application of the drug directly through the mouth cavity.
According to this pipeline analysis report, all the molecules that are currently in the drug development for cystic fibrosis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.